title: Alpha-1 antitrypsin deficiency, a corporate perspective.
abstract: Best-in-class systems have evolved among alpha-1 antitrypsin (AAT) producers, specialty pharmacies and the Alpha-1 Foundation and AlphaNet patient groups. The Genetic Alliance, NORD and other independent parties have recognized the benefits regarding public policy, patient advocacy, medical research, medication adherence, patient identification and health outcomes. Driving the next quantum leap in disease state management for Alpha-1 patients will require strong leadership from both industry and patient groups. Six initiatives are suggested that will sustain best-in-class approaches to identify, treat and even cure Alpha-1 patients.
authors.affiliation: Talecris Biotherapeutics, Research Triangle Park, North Carolina, USA. ldstern1215@gmail.com
authors.forename: Lawrence D
authors.initials: LD
authors.lastname: Stern
mesh_terms: D017277:Drug Approval; D004345:Drug Industry; D005582:Foundations; D015316:Genetic Therapy; D006801:Humans; D007231:Infant, Newborn; D015997:Neonatal Screening; D010344:Patient Advocacy; D012042:Registries; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use; D033581:Stem Cell Transplantation; D000515:alpha 1-Antitrypsin / Q000627:therapeutic use; D019896:alpha 1-Antitrypsin Deficiency / Q000175:diagnosis* / Q000628:therapy*
chemical_list: D015842:Serine Proteinase Inhibitors; D000515:alpha 1-Antitrypsin